IRON

IRON

USD

Disc Medicine Inc. Common Stock

$86.060+3.050 (3.674%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$83.010

Kõrge

$87.125

Madal

$83.010

Maht

0.64M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

3.2B

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.43M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $30.82Praegune $86.060Kõrge $95.95

Seotud uudised

GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Vaata rohkem
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Analyst Upgrades

Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target

Stifel analyst Stephen Willey reinstates Disc Medicine with a Buy and announces $125 price target.

Vaata rohkem
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Vaata rohkem
Disc Medicine to Participate in Upcoming Investor Conferences
Analyst Upgrades

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine with a Overweight and raises the price target from $90 to $115.

Vaata rohkem
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.